VORICONAZOLE-MEDIS voriconazole 50mg tablet blister pack

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

voriconazole, Quantity: 50 mg

Disponible desde:

Medis Pharma Pty Ltd

Designación común internacional (DCI):

Voriconazole

formulario farmacéutico:

Tablet, film coated

Composición:

Excipient Ingredients: lactose monohydrate; magnesium stearate; povidone; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; triacetin; macrogol 3350

Vía de administración:

Oral

Unidades en paquete:

56, 10, 2, 30, 28, 50, 14, 20, 100

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

VORICONAZOLE-MEDIS is indicated for treatment of the following fungal infections:,Invasive aspergillosis.,Serious Candida infections (including C. krusei), including oesophageal and systemic Candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,Serious fungal infections caused by Scedosporium spp and Fusarium spp.,Other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,Prophylaxis in patients who are at high risk of developing invasive fungal infections. The indication is based on studies including patients undergoing haematopoietic stem cell transplantation. This brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets.

Resumen del producto:

Visual Identification: white, round biconvex tablets, debossed 'VC50' on one side and plain on the reverse; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius

Estado de Autorización:

Licence status A

Fecha de autorización:

2015-02-02